| 19.27 0.09 (0.47%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.84  |
1-year : | 29.92 |
| Resists | First : | 22.98 |
Second : | 25.62 |
| Pivot price | 21.07 |
|||
| Supports | First : | 18.7 |
Second : | 15.56 |
| MAs | MA(5) : | 19.56 |
MA(20) : | 21.14 |
| MA(100) : | 22.09  |
MA(250) : | 19.99 |
|
| MACD | MACD : | -1 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 6.1 |
D(3) : | 6.9 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 27.5 | Low : | 13.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ANAB ] has closed above bottom band by 18.0%. Bollinger Bands are 35.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.32 - 19.43 | 19.43 - 19.52 |
| Low: | 18.43 - 18.57 | 18.57 - 18.7 |
| Close: | 19.06 - 19.27 | 19.27 - 19.46 |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Sun, 21 Apr 2024
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies Canada
Thu, 18 Apr 2024
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9% - MarketBeat
Thu, 18 Apr 2024
AnaptysBio, Inc. Forecasted to Post Q1 2024 Earnings of ($1.41) Per Share (NASDAQ:ANAB) - MarketBeat
Tue, 16 Apr 2024
AnaptysBio (NASDAQ:ANAB) Stock Price Up 3.6% - MarketBeat
Fri, 12 Apr 2024
AnaptysBio (NASDAQ:ANAB) Trading Down 8.2% - MarketBeat
Thu, 11 Apr 2024
AnaptysBio (NASDAQ:ANAB) Now Covered by Analysts at Wells Fargo & Company - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 113.5 (%) |
| Shares Short | 4,300 (K) |
| Shares Short P.Month | 4,200 (K) |
| EPS | -6.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.3 |
| Profit Margin | 0 % |
| Operating Margin | -386.5 % |
| Return on Assets (ttm) | -18.5 % |
| Return on Equity (ttm) | -93.5 % |
| Qtrly Rev. Growth | 32.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.64 |
| EBITDA (p.s.) | -5.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -121 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -3.17 |
| PEG Ratio | 0 |
| Price to Book value | 5.82 |
| Price to Sales | 30.05 |
| Price to Cash Flow | -4.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|